### Oxford Academic Health Science Network



### The AHSN Network



# Network Wide Project Portfolio

For the quarter ending 31 March 2023

#### Programme

#### **Programme Details**

**Blood pressure optimisation** programme – Network Wide programme (Develop and deploy) The AHSN blood pressure optimisation (BPO) programme supports local systems to ensure that people with hypertension are appropriately monitored and have their blood pressure and broader cardiovascular risk optimised to prevent heart attacks, strokes, and vascular dementia at scale. The objectives of the programme include: 1) Supporting PCNs to implement the UCLP proactive care frameowrk for hypertension (or analogous framework) to optimise clinical care and self-management in people with hypertension

2) Support PCNs to increase detection of people with hypertension through case-finding interventions 3) Support ICSs to reduce health inequalities by targeting the 20% most deprived populations and other local prioity groups.

#### Q4 Update (Q4 Specific activity/delivery/milestones)

- Continued support at PCN level for hypertension case finding in BLMK.
- Continued engagement with BLMK in developing a hypertension quality improvement programme.

- Engagement with SE PHE/OHID teams to develop a community of practice for HTN for the South East. In 2022/23 the AHSN supported ICBs with HTN improvements at system and practice level. We also made strong connections with regional NHSE and OHID colleagues and have worked with them to develop a community of practice to support ICBs going forward. Whilst the national programme comes to an end in its current form we look forward to continuing to support our ICBs with CVD prevention in general and a specific focus on HTN.

The aim of the AHSN lipid management programme is to embed the NICE/AAC lipid management pathway into clinical practice and ensure that clinicians are aware and confident to prescribe the appropriate therapy to the appropriate patient cohort. The programme also aims to increase diagnosis rates for familial hypercholesterolaemia (FH).


#### Q4 Update (Q4 Specific activity/delivery/milestones)

- Project commencement for the Frimley System Transformation Fund project. Progress to date has included stakeholder engagement, identification of information needs, development of a logic model for evaluation and recruitment of staff to deliver the project.

- Educational webinar delivered for BOB ICB on 26th January
- Support provided to lipidology services with development of a referral proforma
- Final draft of FH business case developed for BOB ICB
- Successful collaborative lipid fund bid developed for BOB ICB

Continued membership of National lipids governance groups, and management of 3 x lipids public partners. Patient information videos on lipids adherence published on HeartUK website. Comms plan for dissemination of videos ongoing, and conversations with companies who manage doctors waiting room screen content taking place, with the view for videos to be displayed in waiting room screens.

**CVD** Prevention – Lipid Management and Familial Hypercholesterolaemia – Network Wide (Deploy)








	Programme	Programme Details
	Inclisiran - Network Wide (Deploy)	Inclisiran forms part of the Network Wide AHSN lipid management pathway but is reported separately as i was introduced into the lipid management pathway in November 2021. The AHSN role is support the adop
		<ul> <li>Q4 Update (Q4 Specific activity/delivery/milestones)</li> <li>Inclisiran activities are included in the lipid management description above. Of particular note for Inclisiran</li> <li>BLMK Halycon project commenced - boosting the capacity of the community lipid service.</li> <li>£170k secured for BOB ICB to support the adoption of the secondary care lipid management pathway.</li> <li>Whilst Inclisiran uptake across the Oxford AHSN region is comparatively low, there has been progress made solution. In 2023/24 we will continue to work to support the appropriate adoption of Inclisiran, as part of the secondary care lipid management pathway.</li> </ul>
	Deteriorating Patient Safety Improvement Programme – Network Wide (Deploy)	During 21/22 we have concentrated on delivery of the phased adoption of deterioration management too national ambition of these tools being used in 80% of non-acute settings by March 2024. For Q4 21/22 the in each preceding quarter. We expect there to be continued work in this area, and to continue to support of <b>Q4 Update (Q4 Specific activity/delivery/milestones)</b> RESTORE2 training has now been provided to 300 care home staff, primarily across Oxfordshire and Frimke which supports homes and support organisations to be self-sufficient in delivering this training in the future RESTORE2 in the remainder of Order of St John Care Trust homes not captured in the earlier pilot in previous by (and in collaboration with) North Oxfordshire Rural Alliance (NORA) Primary Care Network.

### Oxford Academic Health Science Network




onal partners to revise and refine the content of delivery of training. This now provides a aintain the training (ideally through the BOB ICB) so it is sustainable within the systems.

was expected to recommence in Q4; however provision by Frimley Care Homes support service remains limited due to operational pressures. Oxford PSC virtual training continues to help to plug the training gap. RESTORE2 training remains limited in Berks W due to a seconded post. Although virtually delivered training is expected to accelerate roll-out in subsequent quarters, adoption is likely to remain below initial projection.




Programme Details
FREED is an innovative, evidenced based, specialist care package for 16 to 25-year-olds with a first end the barriers to early treatment and provides highly co-ordinated care, with a central focus on the reduced <b>Q4 Update (Q4 Specific activity/delivery/milestones)</b> Consolidation of learning and a report on the successes of the programme has been developed region 27 March. Buckinghamshire's FREED service assessed and engaged 11 patients who joined the FREE The national AHSN FREED programme closed on 31 March 2023. All Eating Disorder services in the B adopting FREED. The service is available to 16-25 year olds with a three-year (or less) undiagnosed end Support will be offered to Oxfordshire's service across the year ahead to ensure that knowledge and B established across the South East will continue within existing structures and allow for good practice Possibility" innovations in Eating Disorders (90 participants), and on Peer Support within Eating Disorder almost 100 clinical staff were trained in FREED (20 from Oxfordshire, 13 from Berkshire, and 5 from Berkshire)
Focus ADHD aims to improve ADHD assessment for school age children. The core of the programme in 2019 place in Berkshire and Oxfordshire CAMHS ADHD Services before the start of the programme in 2019 Wycombe) and Milton Keynes CAMHS has also implemented. <b>Q4 Update (Q4 Specific activity/delivery/milestones)</b> Combined total numbers of tests carried out in Q4 in the new sites (two Buckinghamshire CAMHS sit staff leave and then delays in being able to train new staff. Training is now scheduled for April and ther undertaken at the new sites are 94% of the projected numbers due to this staff turnover issue. The national Focus ADHD programme came to an end in March 23. Buckinghamshire HealthCare True AHSN area that diagnose ADHD in school age children now have Qb Test available to support diagnose Oxford AHSN along with our colleagues in Kent, Surrey and Sussex and Wessex AHSNs, supported a for children's ADHD assessment services with the SE Region. Two members of this Community of Practic back from this role, thus enabling sustainablity of the best practice sharing element of the Focus ADHP
Commission for 2022/3 is focused on reducing harm from opioids prescribed for non-cancer pain. <b>Q4 Update (Q4 Specific activity/delivery/milestones)</b> The partnership we have forged with with the Frimley ICB Pain Collaborative Board sees us well placed monitor progress for this. Once measurement of the workplan is available, we will share this informate In addition, Frimley ICB has announced a MO initiative for 2023/4 which will remunerate GP practices of Structured Medication Reviews; this will provide an important incentive into the system at a time when provide support at system level for this scheme. We also plan to support the Frimley MO education programme to deliver a webinar for Primary Care of








Programme	Programme Details
MedTech Funding Mandate (MTFM) 2022/23 – Network Wide (Deploy)	The MFTM policy aims to accelerate the uptake of selected NICE approved medical devices, diagnost Existing products on the MTFM programme from 2021/22: SecurAcath, Placental Growth Factor (PIG New products added for 2022/23: Urolift, GreenLight XPS, Rezum, PLASMA system (technologies to dilation), Spectra Optia (treatment for sickle cell disease) andThopaz + (digital chest drain)
	Q4 Update (Q4 Specific activity/delivery/milestones)
	Good progress with the MTFM programme during the year:
	<ul> <li>Confirmation of current levels of adoption in the Thames Valley area, allowing targeted activity in</li> <li>Confirmation of the "graduation" of PIGF-based testing, SecurAcath, GammaCore and Heartflow</li> <li>Extensive discussion across Oxford, BLMK, Eastern and Wessex geographies with national and log patients, resulting in area-wide options appraisals being formulated to reconfigure both panned ar</li> <li>System-wide interest confirmed in Thopaz+ through the Thames Valley Respiratory Clinical Network</li> <li>Pursuing the final few contacts to confirm possible value of XprESS adoption in the region</li> </ul>
Mental Health (MH) Patient Safety Improvement Programme – Network Wide	The emphasis of the MH SIP throughout Q4 was Reducing Restrictive Practice (RRP) and local engage experience the challenges of Q4; pressures on Trusts from Covid, staffing vacancies/use of bank staf involved in RRP did not increase from Q4 to Q4 and remained at 6 including Q4 confirmation of a requ
(Deploy)	Q4 Update (Q4 Specific activity/delivery/milestones)
(Deploy)	Our three MH Trusts are engaged with the MH SIP. However Berkshire Healthcare which is working or very slightly in March. After a virtual meeting that repeated the offer of assistance and included an up ward teams to our next live learning event (23 5 23).
	CNWL Milton Keynes Hazel ward are our most advanced project (adoption stage 6) despite changes i with in-person, on-site meeting requires quite a lot of capacity but achieves project progress. Suppo wards are making mixed progress (Ruby adoption stage 5, Sapphire still stage 4) due to some new iss managers and matron in Q4 is really helping. We are also supporting 3 Forensic wards. Kestrel ward pr meetings (now adoption stage 4). Watling worked on first change idea in Q4 (adoption stage 4), and v longer pursuing a RRP project and instead has started an improving inpatient sexual safety project wl
	The biggest change to activity in Q4 has been to begin working with Elysium at Thatcham. We are sup day workshop in March, completed the driver diagram and potential areas for PDSA cycles are already September.
	Q4 saw the QI case study video of Oxford Health's Kennet ward finalised and used at our (South of Er agreed to amalgamate further meetings of the national Forensic Wards network with PICU and Acute









Programme	Programme Details
Polypharmacy – Network Wide (Develop and deploy)	As of April 2022, Polypharmacy: Getting the Balance Right has been agreed as a network wide program implementation. The core principle of the programme is to support local systems address problemat practice; Population Health Management (Pillar 1); Education & Training (Pillar 2) and Public Behaviour
	<b>Q4 Update (Q4 Specific activity/delivery/milestones)</b> The polypharmacy programme will continue to be supported as an AHSN network programme rather the participating Integrated Care Boards (ICB).
	Community of Practice (CoP)
	The second CoP for Frimley ICB was held on 08.02.23. This took place in the evening at the request of people attended. 61 people have expressed an interest in being part of the Frimley CoP.
	The first CoP is being organised for BLMK on 27.04.23. 71 people have expressed an interest in being
	Action Learning Sets (ALS)
	A South-East AHSNS cohort is being planned and promoted for May and June. To date, 16 prescribers being planned to be delivered in 23/24.
	Patient behaviour change campaign
	4 sites have come forward to take part in the pilot to test the Me and My Medicines Campaign. As of 0 contribute to a national level evaluation that will inform wider roll out. A local level focus group is being
	Health inequalities dashboard
	Oxford AHSN have commissioned a polypharmacy health inequalities dashboard from Unity Insights. focus on health inequalities to be included in the programme. The specification has been agreed and
	Communication
	Information about the programme and dates of planned events have been added to the Oxford AHSN Alignment with ICB plans
	Polypharmacy has been included in medicines optimisation and medicines safety work plans for Friml
Reducing inappropriate high dose opiate prescriptions for	The AHSN network has developed a whole systems approach to reducing harm from opioids to suppo
non-cancer pain - National (Develop)	<b>Q4 Update (Q4 Specific activity/delivery/milestones)</b> See Medicines Safety Improvement Programme above












Programme	Programme Details
Transforming Wound Care - Network Wide (Develop and deploy)	In 2022/23 we have started a programme of spread and adoption of the National Wound Care Strateg We will be working with ICS and Trust stakeholders to develop effective delivery to reduce leg ulcer programme starts in Q1.
	<b>Q4 Update (Q4 Specific activity/delivery/milestones)</b> Successfully launched dedicated lower limb clinic within Frimley Health and Care ICS on the 4th April 1 Feedback from the TES in Frimley Health and Care ICS has been very positive. The clinical nursing ma implement compression immediately on presentation of wound has worked really well. Feedback from on leg wound management. This has led to sparking other ideas of how to improve operational efficient prompt referrals to the specialist services. They have a number of patient cases who have already be are hoping to publish some of these successes as case studies.
Maternity and Neonatal Safety - Deterioration - Network Wide (Deploy)	New National Maternity Early Warning Score tool designed to focus on early identification, escalation Currently Phase 1 of pilot testing. Q4 Update (Q4 Specific activity/delivery/milestones) Evaluation of pilot phases by NHSE and plans for implementation when NHSE are ready-Oxford are a their trusts wide e-obs digital system.
Maternity and Neonatal Safety - Preterm Optimisation - Network Wide (Develop and Deploy)	Optimisation of the preterm baby is a key priority outlined in Maternity and Neonatal Safety improved Preterm Birth before 27 weeks. There are several elements within the optimisation care bundle which trusts are required to work tog steroid and magnesium usage and early colostrum and breast milk which will ensure that the preterm We are working collaboratively with a diverse group of stakeholders to improve outcomes for this preterm <b>Q4 Update (Q4 Specific activity/delivery/milestones)</b> Scoping discussions with Bucks New University re design and development of a simulation based mustakeholder engagement exercises. Scoping costing to 'professionalise' the content of the antenatal counselling workshops with OxSTaF
Rapid Uptake Products - PCSK9i - National (Deploy)	AAC RUP (forms part of the national lipid management programme) <b>Q4 Update (Q4 Specific activity/delivery/milestones)</b> This forms part of the national lipid mangagement programme - commentary given above.







Programme	Programme Details
Rapid Uptake Products - High Intensity Statins - National (Deploy)	AAC RUP (forms part of the national lipid management programme) <b>Q4 Update (Q4 Specific activity/delivery/milestones)</b> This forms part of the national lipid mangagement programme - commentary given above.
Rapid Uptake Products - Fractionally exhaled Nitrous Oxide (FeNO) - National (Deploy)	AAC RUP - Fractional Exhaled Nitric Oxide (FeNO) project, for the diagnosis and management of asthm of FeNO testing. <b>Q4 Update (Q4 Specific activity/delivery/milestones)</b> We procured an additional 7 Bedfont FeNO monitors for the BOB ICS. 6 of these will be used to help del funded through the Innovation for Healthcare Inequalities Programme (InHIP). We helped Healthier Ox EMIS clinical IT system to facilitate sharing of a single FeNO monitor across a PCN. We achieved the year from NHSE (February 2023) shows that Oxford AHSN currently tops the AHSN leader board for most Fe
Rapid Uptake Products - Asthma Biologics - National (Deploy)	<ul> <li>AAC RUP - Asthma Biologics programme, the programme is aiming to improve care for severe asthma treatment escalation to biologics for appropriate patients</li> <li><b>Q4 Update (Q4 Specific activity/delivery/milestones)</b></li> <li>Work on various comms activities to raise awareness about the impact of the Asthma Biologics Program FeNO and Asthma Biologics into one single asthma programme narrative, "Transforming Asthma Pathwa story about the innovative and transformative work continuing across the asthma pathway.</li> <li>Continue to raise awareness about available resources for HCPs to improve uptake of e-learning modul participants have provided positive feedback on modules</li> <li>All (9) PTF evaluation reports and clarification questions were re.viewed and work continued on writing Programme. Three case studies drafted to show good examples of the delivered PTF projects.</li> <li>My AsthmaBiologic App, a homecare monitoring app - 2 pilot sites went live and 144 patients using the Successfully delivered:</li> <li>Final joint FeNO/AB AHSN Leads meeting; great reflections received from Vicky Spellacy (AAC), Stur statements, such as "the programme shows power of the AHSNs!"</li> <li>Final AB PWG meeting: positive reflections received from National Respiratory Clinical Director (NH)</li> <li>Joint presentation with Wessex AHSN the Asthma Biologics and FeNO national programmes at the National:</li> <li>The AAC RUP Asthma Biologics Programme closed on 31st March 2023. The second year, 2022/23, of programme was led, designed and delivered in collaboration (working with AAC, AHSN Network, Indust pathway, from identification and diagnosis to monitoring and treatment.</li> </ul>

#### Page 7 of 7

